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Abstract
Perfluoroalkyl acids (PFAAs) are detectable in human blood. PFAA exposure may contribute to androgen receptor (AR)-
related health effects such as prostate cancer (PCa). In Norway and Sweden, exposures to PFAAs and PCa are very real 
concerns. In vitro studies conventionally do not investigate PFAA-induced AR disruption at human blood-based concentra-
tions, thus limiting application to human health. We aim to determine the endocrine disrupting activity of PFAAs based 
upon human exposure levels, on AR transactivation and translocation. PFAAs (PFOS, PFOA, PFNA, PFDA, PFHxS, and 
PFUnDA) were tested at concentrations ranging from 1/10 × to 500 × relative to human blood based upon the exposure 
levels observed in a Scandinavian population. Translocation was measured by high content analysis (HCA) and transactiva-
tion was measured by reporter gene assay (RGA). No agonist activity (translocation or transactivation) was detected for any 
PFAAs. In the presence of testosterone, AR translocation increased following exposure to PFOS 1/10 × and 100 ×, PFOA 
1/10 ×, and PFNA 1 × and 500 × (P < 0.05). In the presence of testosterone, PFOS 500 × antagonised AR transactivation, 
whereas PFDA 500 × increased AR transactivation (P < 0.05). PFAAs may contribute to AR-related adverse health effects 
such as PCa. PFAAs can disrupt AR signalling via two major components: translocation and transactivation. PFAAs which 
disrupt one signalling component do not necessarily disrupt both. Therefore, to fully investigate the disruptive effect of 
human exposure-based contaminants on AR signalling, it is imperative to analyse multiple molecular components as not all 
compounds induce a disruptive effect at the same level of receptor signalling.
Keywords Endocrine disrupting chemical · Translocation · Perfluoroalkyl acid · Persistent organic pollutant · Androgen 
receptor · High content screening
Introduction
Perfluoroalkyl substances (PFAS) are organic compounds 
with hydrogen atoms replaced by fluorine atoms with the 
exception of the functional group. Perfluoroalkyl acids 
(PFAAs) are a class of PFAS. Perfluorooctane sulfonic 
acid (PFOS) is a fully fluorinated anion that was intention-
ally produced for commercial use in electric and electronic 
parts, firefighting foam, and textiles. PFOS may uninten-
tionally be produced as the degradation product of simi-
lar anthropogenic chemicals (Buck et al. 2011). PFOS and 
related PFAAs have been categorised as new or emerging 
persistent organic pollutants (POPs) due to substantial bio-
accumulation and biomagnifying properties (Buck et al. 
2011; Olsen et al. 2009). Consequently, PFAAs are ubiqui-
tous and stable chemicals widely detected in humans (Buck 
et al. 2011; Kishi et al. 2015). Unlike classical POPs, such 
 * L. Connolly 
 l.connolly@qub.ac.uk
1 School of Biological Sciences, Institute for Global Food 
Security, Queen’s University Belfast, 19 Chlorine Gardens, 
Belfast, Northern Ireland BT9 5DL, UK
2 Prostate Cancer UK/Movember Centre of Excellence, Centre 
for Cancer Research and Cell Biology, School of Medicine, 
Dentistry, and Biomedical Sciences, Queen’s University 
Belfast, Belfast, Northern Ireland BT9 7AE, UK
3 Department of Production Animal Clinical Sciences, Faculty 
of Veterinary Medicine, Norwegian University of Life 
Sciences, Sentrum, Post-box 369, 0102 Oslo, Norway
4 Lab Animal Unit, Department of Administration, National 
Institute of Occupational Health, P.O. Box 5330, Oslo, 
Norway
5 Nuffield Department of Surgical Sciences, Level 6, John 
Radcliffe Hospital, University of Oxford, Headington, 
Oxford OX3 9DU, UK
 J. McComb et al.
1 3
as dichlorodiphenyldichloroethylene, PFAAs do not parti-
tion into lipid-based tissues. Instead PFAAs have affinity 
for blood and liver-based proteins (Sheng et al. 2016), thus 
potentially increasing bioavailability in many bodily tissues.
Exposure to PFAAs may contribute to adverse health 
effects by disrupting hormonal signalling (Vogs et al. 2019; 
Steenland et al. 2010; Lei et al. 2015). Exogenous substances 
which disrupt hormonal signalling are called endocrine dis-
rupting chemicals (EDCs). In Scandinavian countries such 
as Norway and Sweden, exposure to PFAAs is an environ-
mental and health concern (Haug et al. 2009; Banzhaf et al. 
2017). For instance, PFOS levels in Norwegian men have 
sharply increased since 1977 with a plateau in the mid-1990s 
(Haug et al. 2009). Despite this, long-chain PFAAs such as 
those used in the present study have high structural integrity 
and long elimination half-lives; therefore, human exposure 
is still a very relevant concern (New Jersey Drinking Water 
Quality Institute Health Effects Subcommittee 2015; Butt 
et al. 2007; Li et al. 2018; Olsen et al. 2007).
In Scandinavian countries, such as Norway and Swe-
den, prostate cancer (PCa) is also a major health concern 
as they rank sixth and seventh, respectively, in the world 
for age-standardised PCa risk (Bray et al. 2018). In a recent 
case-control study, serum concenrations of PFAAs  were 
analysed among 201 cases with PCa and 186 population-
based control subjects (Hardell et al. 2014). This study found 
that blood-based levels of perfluorodecanoic acid (PFDA) 
were associated with PCa risk (Hardell et al. 2014). Addi-
tionally, PFOS, perfluorooctanoic acid (PFOA), perfluorono-
nanoic acid (PFNA), PFDA, perfluorohexane sulfonic acid 
(PFHxS), and perfluoroundecanoic acid (PFUnDA) yielded 
statistically higher odds ratio in cases with first-degree rela-
tives with PCa (Hardell et al. 2014). This study shows a clear 
interaction between genetic and environmental factors on the 
etiology of PCa; however, the authors report the suspected 
mechanism of action to be unknown.
PCa is an age- and endocrine-related cancer driven pri-
marily by overstimulation of androgenic signalling (Heinlein 
and Chang 2004). Androgenic and anti-androgenic effects 
are executed molecularly by the androgen receptor (AR). 
The AR is a member of the nuclear receptor family that acts 
as a transcription factor regulating critical molecular and 
cellular events such as growth, proliferation, and secretion 
of prostate-specific antigen (PSA). The AR is activated by 
endogenous hormones (Guiochon-Mantel et al. 1996; Pratt 
et al. 1999; Black et al. 2004). Androgens such as testos-
terone and dihydrotestosterone (DHT) bind cytoplasmic 
AR and induce translocation to the nucleus whereby AR 
homodimers bind and regulate the transcriptional activity 
of target genes (Cutress et al. 2008). Successful receptor 
transactivation is dependent on receptor translocation yet 
in vitro-based studies tend to report on AR transactivation 
of a reporter plasmid transfected with a luciferase construct 
as their only (anti-) androgenic experimental endpoint. 
Functionally, the AR is involved in molecular and cellular 
processes beyond transactivation. Therefore, monitoring 
upstream translocation will reveal AR disrupting effects that 
may indicate more complex molecular pathways of endo-
crine disruption.
The aim of this study is to test human-based exposure 
levels of PFAAs (Berntsen et al. 2017), including PFOS, 
PFOA, PFNA, PFDA, PFHxS, and PFUnDA, for a potential 
endocrine disrupting effect on two components of AR sig-
nalling. The first is translocation, using high content analysis 
(HCA), to detect agonist and antagonist effects. The second 
is transactivation, using reporter gene assay (RGA), to also 
detect agonist and antagonist effects. Combining both assays 
will allow for the detection of a new mechanism of action 
by which human-based exposure levels of PFAAs induce 
a disruptive effect on AR signalling, as reporting solely 
based upon one component of AR signalling may lead to 
potentially harmful PFAAs being categorised as having no 
endocrine disrupting activity. This will serve as a valuable 
screening process to detect for endocrine disruptors which 
mediate AR-related disruption via gene transactivation or 
via an alternative biological pathway linked to translocation.
Materials and Methods
Reagents
All reagents were purchased from Life Technologies (Pais-
ley, UK) unless otherwise stated. Testosterone, phosphate 
buffered saline (PBS), dimethyl sulfoxide (DMSO), and 
MTT powder were purchased from Sigma-Aldrich (Poole, 
Dorset, UK). Perfluoroalkyl acids (PFAAs) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) except 
for PFHxS which was purchased from Santa Cruz (Dallas, 
USA). The luciferase reporter gene assay kit was purchased 
from Promega (Southampton, UK). Hoechst 33342 was pur-
chased from Thermo Scientific (UK).
Perfluoroalkyl Acids
PFAAs were based on concentrations measured in human 
blood, according to recent studies of the Scandinavian popu-
lation (Berntsen et al. 2017), as shown in Table 2. All PFAAs 
(PFOS, PFOA, PFNA, PFDA, PFHxS, and PFUnDA) were 
tested at 1/10 ×, 1 ×, 50 ×, 100 ×, and 500 × relative to 
blood-based concentrations levels, using stably transfected 
AR cell lines TARM-Luc (RGA) and recombinant AR U-2 
OS (HCA).
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Cell Culture
All cells were routinely cultured in 75  cm2 tissue culture 
flasks (Nunc, Roskilde, Denmark) at 37 °C with 5%  CO2 
and 95% humidity.
TARM‑Luc Cells
TARM-Luc cells were obtained   from the University of 
Liege (Dr Marc Muller) and previously generated by Wil-
lemsen and colleagues (Willemsen et al. 2004). TARM-Luc 
cells are androgen-sensitive cells with a pSV-AR0 expres-
sion vector which express a luciferase reporter protein in 
response to androgens. TARM-Luc cells were cultured in 
DMEM Glutamax™ supplemented with 10% foetal bovine 
serum (FBS). For seeding and exposures, TARM-Luc cells 
were cultured in DMEM Glutamax™ supplemented with 
10% charcoal-stripped (CCS)-FBS.
Recombinant AR U‑2 OS Cells
Recombinant U-2 OS cells with an AR (GenBank Acc. 
NM_000044) coding sequence (AR U-2 OS) fused to the 
C-terminus of an enhanced green fluorescent protein (EGFP) 
stably integrated onto the human osteosarcoma U-2 OS line 
(ATCC® HTB-96™) were cultured in DMEM Glutamax™ 
supplemented with 10% FBS, 1% penicillin–streptomycin 
(P/S), 2 mM l-Glutamine, and 0.5 mg/ml G418 sulphate. For 
experiments, cells were seeded in DMEM Glutamax™ sup-
plemented with 10% CCS-FBS, 1% P/S, 2 mM l-Glutamine, 
and 0.5 mg/ml G418 sulphate. For exposures, cells were 
cultured in DMEM Glutamax™ supplemented with 1% P/S 
and 2 mM l -Glutamine.
Reporter Gene Assay
The AR reporter gene assay was performed as previ-
ously described (Frizzell et  al. 2011). Briefly, TARM-
Luc cells were seeded 40,000 cells per well in specialised 
Control
(0.2% DMSO in media)
No EFFP-AR translocaon or AR 
nuclear foci formaon in cell nucleus
Antagonist
(10 µM enzalutamide)
EGFP-AR translocates to the nucleus 
but forms limited AR nuclear foci
Agonist
(50 nM testosterone)
EGFP-AR translocates to the nucleus 
and forms mulple AR nuclear foci
Cytoplasm
Nucleus
Ex
po
se
d 
ce
lls
Unexposed recombinant AR U-2 OS cell
EGFP-AR is localised in the cytoplasm
Fig. 1  Illustration of the AR translocation event. In unstimulated 
(or solvent control) recombinant AR U-2 OS cells, enhanced green 
fluorescent protein androgen receptor (EGFP-AR) is localised to the 
cytoplasm of the cells. Upon exposure to androgens such as testoster-
one, the EGFP-AR translocates to the cell nucleus whereby it binds 
to AREs in the promoter region of target genes. The HCA platform 
measures the formation of nuclear foci. For an agonist response, 
there is an increase in nuclear foci. Upon exposure to anti-androgens 
such as enzalutamide, EGFP-AR can still translocate to the nucleus; 
however, it is prevented from binding to AREs. For an antagonist 
response, there is a reduction in nuclear foci compared to the posi-
tive control. The ThermoFisher HCA platform refers to the formation 
of nuclear foci as “spots” and is measured using the Spot Detector 
bioapplication
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white-walled, clear flat-bottomed 96-well plates (Greiner, 
Bio-One, Frickenhausen, Germany). Plates were incu-
bated at 37 °C 5%  CO2 overnight. Subsequently, cells were 
exposed to PFAAs in the presence of the solvent control 
(SC) DMSO (0.2% v:v in media) at 1/10 ×, 1 ×, 50 ×, 100 
×, and 500 × relative to blood level for the agonist test. For 
the antagonist test, the positive control (PC) testosterone 
was used at 50 nM and each PFAA was combined with the 
PC at 1/10 ×, 1 ×, 50 ×, 100 ×, and 500 × relative to blood 
level. Exposure of cells lasted 48 h. Cells were lysed with 1 
Fig. 2  Metabolic effect of 48-h PFAA exposure in the  TARM-Luc 
cell line. Metabolic activity, as determined by MTT, of TARM-Luc 
cells following 48-h exposure to PFAAs. Results are representative of 
3 independent exposures (n = 3, mean ± SEM). *P < 0.05; **P < 
0.01; ***P < 0.001. Exposure time = 48 h
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× cell lysis reagent facilitated by agitation. Plates were then 
read using a Mithras Multimode Reader (Berthold, Other, 
Germany) which injected each well with 100 µl of luciferase 
(made according to manufacturer’s protocol; consisting of 
luciferase assay buffer and luciferase assay substrate) and 
measured the response of each well via detection of lumines-
cence. TARM-Luc cells upon AR transactivation expressed 
a luciferase signalling protein allowing for the detection of 
both agonist and antagonist responses which were compared 
to the SC and PC, respectively.
Fig. 3  Metabolic effect of 6-h PFAA exposure in the  recombinant 
AR U-2 OS cell line. Metabolic activity, as determined by MTT, of 
recombinant AR U-2 OS cells following 6-h exposure to PFAAs. 
Results are representative of three independent exposures (n = 3, 
mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001. Exposure time 
= 6 h
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High Content Analysis
Recombinant AR U-2 OS cells were seeded 6,000 cells per 
well in black-walled 96-well plates with clear flat bottoms 
(Greiner, Germany). Plates were incubated at 37 °C 5%  CO2 
overnight. Subsequently, cells were exposed as described 
above in "Reporter Gene Assay" section reporter gene assay. 
After 6 h of exposure, cells were washed with 1 × PBS and 
fixed using 5% formalin. Cells were then washed twice with 
1 × PBS and subsequently stained using 2 µM Hoechst 
33342. Plates were read using CellInsight NXT High Con-
tent Analysis Platform (ThermoFisher Scientific, UK) using 
Spot Detector Bioapplication which measures the transloca-
tion activity of the AR allowing for the detection of agonist 
and antagonist responses which were compared to the SC 
and PC, respectively.
Recombinant AR U-2 OS cells express a stably trans-
fected AR fused with an enhanced green fluorescent protein 
(EGFP-AR). A wavelength of 485 nm was used to detect 
EGFP-AR localisation upon successful AR binding to andro-
gen response elements (AREs). This is illustrated in Fig. 1. 
The channel 2 experimental endpoint measuring successful 
receptor translocation was spot count per object:
Hoechst 33342 was used to counter stain cell nuclei in 
each well. A wavelength of 386 nm was used to detect bind-
ing of Hoechst 33342 to nuclei. Output parameters included 
object count (cell number), nuclear area, and nuclear 
intensity.
Total number of spots (AR) ÷ nuclear (cell) number
= spot count per object.
MTT Assay
TARM-Luc and recombinant AR U-2 OS cells were seeded 
in clear flat-bottomed 96-well plates (Nunc, Roskilde, Den-
mark) and followed the same seeding and exposure protocol 
as described. After 48 h (TARM-Luc) or 6 h (recombinant 
AR U-2 OS) of exposure, cells were incubated with MTT 
(0.33 mg/ml) solution. Healthy cells convert soluble yel-
low MTT solution to insoluble purple formazan crystals. 
Formazan crystals were solubilised in DMSO facilitated by 
agitation at 37 °C. Optical density was measured, as previ-
ously described (Shannon et al. 2019), using a Sunrise spec-
trophotometer at 570 nm with a reference filter at 630 nm 
(TECAN, Switzerland). Metabolic activity was calculated 
as a percentage absorbance of the sample compared with 
the absorbance of the SC. Metabolic activity was used as an 
indirect measure of gross cellular health.
Statistical Analysis
All experiments were carried out in triplicate and in three 
independent exposures. Data were analysed using Micro-
soft Excel in addition to Graphpad PRISM software, version 
5.01 (San Diego, CA). Values are expressed as the mean of 
9 triplicates from the 3 independent exposures ± standard 
error of the mean (SEM). Data are expressed as a percent-
age of the solvent or positive controls, where applicable. 
Analysis carried out includes (i) one-way ANOVA followed 
by Dunnett’s procedure for multiple comparisons; the mean 
concentrations were tested for significant difference at the 
95% confidence level. Significant values were as follows: P 
≤ 0.05 (*), P ≤ 0.01 (**), and P ≤ 0.001 (***).
Fig. 4  Pre-lethal cytotoxicity markers following 6-h exposure to 
PFAAs in the recombinant AR U-2 OS cell line. a Changes in object 
count in response to PFAAs compared to SC. b Changes in nuclear 
area in response to PFAAs compared to SC. Changes for the nuclear 
intensity parameter can be found in Table 2. Results are representa-
tive of three independent exposures (n = 3, mean ± SEM). *P < 0.05; 
**P < 0.01; ***P < 0.001. Only significant results are presented for 
nuclear intensity parameter
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Results
Endocrine disrupting activity of 6 PFAAs relevant to human 
exposure levels on AR transactivation and translocation was 
investigated. Concentrations of PFAAs were based upon the 
exposure levels detected in Scandinavian blood (Berntsen 
et al. 2017).
Cytotoxicity and Cellular Health
Gross cytotoxicity was evaluated in the AR RGA (TARM-
Luc) and AR HCA (recombinant AR U-2 OS) cell models 
by quantifying metabolic activity using MTT conversion 
(Figs. 2 and 3, respectively). In AR RGA (TARM-Luc) 
cells, PFOS 1/10 × and 50 ×, PFOA 1 ×, and PFNA 1 × 
decreased metabolic by 13.9% ± 3.4 SEM, 13.3% ± 5 SEM, 
15.5% ± 4.1 SEM, and 19.6% ± 4.1 SEM, respectively 
(Fig. 2a–c). Conversely, PFHxS 500 × and PFUnDA 100 
Table 1  Summary of gross cellular and pre-lethal cytotoxicity results for TARM-Luc (RGA) and recombinant AR U-2 OS (HCA) cell lines
a Concentration relative to blood level, based upon the exposure profile of Scandinavian population (Berntsen et al. 2017)
b Cytotoxicity percentage is normalised against solvent control which was set to 100%
c TARM-Luc cells were used to measure metabolic activity concomitantly with AR RGA 
d AR U-2 OS cells were used to measure metabolic activity concomitantly with HCA
*P < 0.05, **P < 0.01, ***P < 0.001
PFAA Concentrationa Cytotoxicity (% ± SEM)b
Markers of gross cellular health Pre-lethal cytotoxicity markers
MTT (TARM-Luc)c MTT (AR U-2 OS)d, Cell number Nuclear area Nuclear intensity
PFOS 1/10 × 86.1 ± 3.4* 102.9 ± 2.1 101.1 ± 4.0 101.6 ± 1.9 103.3 ± 1.8
1 × 87.2 ± 3.3 105.1 ± 1.4 92.2 ± 5.9 102.3 ± 1.5 104.8 ± 1.2
50 × 86.7 ± 5.0* 100.7 ± 1.9 89.3 ± 6.2 100.8 ± 2.0 107.2 ± 2.1**
100 × 90.7 ± 4.5 98.2 ± 2.0 94.3 ± 6.6 99.7 ± 2.3 109.3 ± 2.8***
500 × 97.8 ± 4.8 109.7 ± 3.2** 76.8 ± 3.7** 99.9 ± 1.8 109.2 ± 2.1***
PFOA 1/10 × 90.8 ± 3.8 96.7 ± 6.2 87.5 ± 7.2 105.0 ± 1.4* 98.7 ± 1.7
1 × 84.5 ± 4.1* 92.1 ± 5.5 104.6 ± 7.4 101.7 ± 1.4 100.6 ± 1.6
50 × 93.0 ± 4.1 103.1 ± 2.6 107.9 ± 6.3 101.0 ± 0.9 100.8 ± 1.6
100 × 92.6 ± 3.3 101.4 ± 2.7 92.9 ± 7.5 100.4 ± 1.3 102.9 ± 1.2
500 × 94.4 ± 4.3 99.6 ± 3.2 97.6 ± 6.3 102.6 ± 1.3 102.4 ± 1.4
PFNA 1/10 × 89.6 ± 8.8 96.2 ± 3.6 96.0 ± 7.5 100.3 ± 1.1 103.3 ± 1.5
1 × 80.4 ± 4.1* 98.5 ± 1.6 97.9 ± 5.9 99.0 ± 0.9 106.0 ± 2.0*
50 × 103.5 ± 4.3 102.0 ± 1.4 91.9 ± 6.1 98.1 ± 1.2 108.1 ± 1.8**
100 × 97.2 ± 5.3 97.8 ± 2.2 93.0 ± 5.4 98.8 ± 1.5 108.1 ± 1.8**
500 × 92.5 ± 4.7 95.4 ± 2.7 78.5 ± 3.6* 97.5 ± 1.9 112.6 ± 2.1***
PFDA 1/10 × 101.8 ± 5.0 98.4 ± 1.4 101.3 ± 4.8 98.9 ± 0.7 105.5 ± 1.2**
1 × 98.4 ± 7.6 105.8 ± 2.2 101.3 ± 6.0 98.7 ± 1.1 107.3 ± 0.8***
50 × 100.1 ± 3.4 100.6 ± 4.3 93.8 ± 7.0 96.8 ± 0.8* 109.3 ± 1.6***
100 × 101.3 ± 3.0 101.6 ± 2.5 96.0 ± 5.4 95.1 ± 1.2*** 113.5 ± 2.6***
500 × 103.5 ± 4.8 101.2 ± 3.5 77.8 ± 5.1*** 96.8 ± 0.7* 111.5 ± 1.4***
PFHxS 1/10 × 105.3 ± 3.2 105.8 ± 7.7 93.5 ± 5.5 97.4 ± 1.2 106.0 ± 1.6***
1 × 106.0 ± 2.9 100.3 ± 2.5 102.6 ± 8.1 99.3 ± 1.4 102.5 ± 1.2
50 × 103.3 ± 1.8 100.2 ± 1.7 103.9 ± 6.5 98.0 ± 1.4 104.3 ± 1.7*
100 × 107.4 ± 2.4 101.2 ± 3.8 105.5 ± 8.1 98.5 ± 1.0 104.2 ± 1.1*
500 × 111.8 ± 4.7* 100.3 ± 3.9 103.1 ± 6.9 97.7 ± 1.2 104.3 ± 1.2*
PFUnDA 1/10 × 106.8 ± 1.7 101.8 ± 3.7 102.1 ± 6.2 95.0 ± 1.3** 109.4 ± 2.8**
1 × 102.0 ± 1.7 100.2 ± 2.8 102.2 ± 5.6 96.1 ± 1.7 106.5 ± 2.1
50 × 101.1 ± 5.2 94.6 ± 2.8 101.4 ± 6.5 95.0 ± 1.6** 110.7 ± 3.2***
100 × 113.0 ± 3.1* 105.9 ± 3.6 94.7 ± 4.4 96.8 ± 0.9 108.1 ± 0.4*
500 × 108.0 ± 4.1 99.4 ± 2.6 86.7 ± 6.1 92.6 ± 1.5*** 114.7 ± 2.7***
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× increased metabolic activity by 11.8% ± 4.7 SEM and 
13% ± 3.1 SEM, respectively (Fig. 2e, f). For HCA (AR 
U-2 OS) cells, PFOS 500 × increased metabolic activity by 
9.7% ± 3.2 SEM (Fig. 3a). Additionally, cellular health in 
the AR translocation assay (recombinant AR U-2 OS) was 
monitored using a HCA platform. Here, multiple parameters 
for pre-lethal cytotoxicity for nuclear morphology (nuclear 
area, nuclear intensity) were measured, in addition to gross 
cytotoxicity (cell number). PFOS, PFNA, and PFDA, all at 
500 × blood level, deceased cell number by 23.2% ± 3.7 
SEM, 21.5 ± 3.6 SEM, and 22.2% ± 5.1 SEM, respec-
tively (Fig. 4a). Minor changes in nuclear area (Fig. 4b) and 
nuclear intensity (Table 2) were observed across most sam-
ples. A full summary of the cytotoxicity and cellular health 
results is shown in Table 1.   
Androgen Receptor (AR) mediated Reporter Gene 
Transactivation
At the concentrations tested (1/10 ×, 1 ×, 50 ×, 100 ×, and 
500 ×), none of the PFAAs tested showed any agonist activ-
ity on AR transactivation when compared to the SC. When 
screened for antagonism, in the presence of testosterone, 
PFOS 500 × antagonised AR transactivation by 19.7% ± 
5.4 SEM compared to the PC (P < 0.05, Fig. 5). In contrast, 
PFDA 500 × increased AR transactivation by 26.6% ± 11.5 
SEM compared to the PC alone (P < 0.05, Fig. 5). A sum-
mary of the observed effect on AR transactivation can be 
seen in Table 2.
Translocation of the Androgen Receptor 
in the Recombinant AR U‑2 OS Model
At the concentrations tested (1/10 ×, 1 ×, 50 ×, 100 ×, and 
500 ×), none of the PFAAs tested showed any agonist activ-
ity on AR translocation when compared to the SC (Fig. 6 
and Table 2). However, when tested in the presence of tes-
tosterone, PFOS 1/10 ×, 100 ×, and 500 ×, PFOA 1/10 ×, 
and PFNA 1 × and 500 × significantly increased AR trans-
location activity by 28.5% ± 9.1 SEM, 27.9% ± 9.2 SEM, 
41.2% ± 10.1 SEM, 30.4% ± 12 SEM, 26.4% ± 9 SEM, and 
42% ± 6.9 SEM, respectively, compared to the PC alone 
(P < 0.05, Fig. 6). Images from the translocation assay (for 
SC, PC, PC + PFOS 1/10 × and 100 ×, PFOA 1/10 ×, and 
PFNA 1 × only) are shown in Fig. 6. The remaining PFAAs, 
PFDA, PFHxS, and PFUnDA, did not significantly change 
AR translocation activity compared to the PC (Table 2). A 
summary of the observed effect on AR transactivation can 
be seen in Table 2.
Discussion
Human exposure-based PFAAs were evaluated for their 
potential endocrine disruptive effect on AR signalling using 
in vitro cell models. Two major components of AR signal-
ling were assayed; transactivation (by RGA) and transloca-
tion (by HCA). Additionally, assays indicative of cellular 
health were carried out concomitantly with each assay to 
control for sample cytotoxicity. Cytotoxicity and cellular 
health are important to consider for cell-based assays as the 
experimental endpoints may be impacted by sample-induced 
cytotoxicity (Mamsen et al. 2017; Eke et al. 2017). Two 
cytotoxicity assays were utilised as assay controls: MTT 
assay and HCA.
In a similar study, PFOS and PFDA were found to be 
cytotoxic at ≥ 1 ×  10–4 molar or 1000 µM as determined by 
MTT (Kjeldsen and Bonefeld-Jorgensen 2013). Presently, 
however, the upper limit concentration of PFOS and PFDA 
was 2.1 µM and 0.02 µM, respectively. This illustrates the 
need for human-based exposure levels to be used in vitro if 
conclusions regarding human health are to be made. In the 
present study, PFAA concentrations are based upon blood-
based levels measured in a Scandinavian population (Bern-
tsen et al. 2017) as shown in Table 2, and thus have more 
relevant implications for human health.
Cytotoxicity results highlight limitations of the MTT 
assay used to determine sample-induced cytotoxicity. In 
the same experimental setting, recombinant AR U-2 OS 
cells following exposure to PFOS 500 × increased meta-
bolic activity as determined by MTT; however, cell num-
ber decreased as measured by HCA. Thus, two markers of 
gross cellular health directly contradict one another. The 
Fig. 5  Transactivation effects of 48-h exposure to PFAAs on the 
androgen receptor in the TARM-Luc cell line. Analysing transactiva-
tion of the AR following PFAA exposure. Results are representative 
of three independent exposures (n = 3, mean ± SEM). *P < 0.05; 
**P < 0.01; ***P < 0.001. Only significant results are presented
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MTT assay is dependent on the oxidoreductase enzyme 
succinate dehydrogenase (SDH), located in the inner mito-
chondrial membrane, to catalyse the reduction of the tetra-
zolium dye MTT to insoluble formazan (Chacon et al. 1997; 
Roomi et al. 2016). Therefore, it would be more appropri-
ate to implicate changes in MTT as changes in metabolic 
activity. Additional limitations of the MTT assay include 
bioavailability of experimental compounds with fluctua-
tions in cell seeding density (Riss et al. 2004), MTT-induced 
toxicity (Lu et al. 2012), and MTT incubation time (Riss 
et al. 2004). Given the limitations of the MTT assay, future 
investigations which directly measure gross cellular toxicity 
should be used.
Table 2  Summary of androgen receptor disrupting affects following PFAA exposure for RGA and HCA AR model cell lines
a AR translocation as measured by HCA in the present study
b Concentrations used in the present study presented as both pM and relative to blood level based upon human Scandinavian population (Bernt-
sen et al. 2017)
c LOEC; lowest observed effect concentration as reported by recent study (Kjeldsen and Bonefeld-Jorgensen 2013)
d Agonist activity for RGA and HCA expressed as % of solvent control which was normalised against testosterone standard curve ranging from 
0.01 to 100 nM for HCA and 0.5 nM to 1000 nM for RGA. Solvent control set to 0%. Top point of curve set to 100%
e Antagonist activity for RGA and HCA expressed as % of solvent control which was normalised against testosterone standard curve ranging 
from 0.01 to 100 nM for HCA and 0.5 nM to 1000 nM for RGA. Solvent control set to 0%. Top point of curve set to 100%
* P < 0.05, **P < 0.01, ***P < 0.001
PFAA AR transactivation AR  translocationa Concentrationb
Antago-
nist 
(LOEC)c
Agonistd (% ± SEM) Antagoniste (% ± SEM) Agonistd (% ± SEM) Antagoniste (% ± SEM) pM Relative 
to blood 
level
PFOS 50 µM − 2.4 ± 1.4 107.1 ± 4.7 0.4 ± 0.2 128.5 ± 9.1* 415.221 1/10 ×
− 3.3 ± 0.9 111.4 ± 5.4 0.1 ± 0.1 122.0 ± 9.4 4152.21 1 ×
− 3.6 ± 0.8 104.6 ± 5.1 0.1 ± 0.1 118.7 ± 7.2 207,610.5 50 ×
− 3.7 ± 0.7 95.9 ± 6.5 0.2 ± 0.2 127.9 ± 9.2* 415,221 100 ×
− 2.8 ± 1.3 80.3 ± 5.4* 0.1 ± 0.1 141.2 ± 10.1*** 2,076,105 500 ×
PFOA 100 µM − 2.7 ± 1.1 100.1 ± 3.2 0.1 ± 0.1 130.4 ± 12.0* 42.094 1/10 ×
− 4.0 ± 0.7 100.1 ± 5.4 0.2 ± 0.2 107.2 ± 11.6 420.94 1 ×
− 4.0 ± 0.8 89.8 ± 5.1 0.5 ± 0.2 116.3 ± 8.2 21,047 50 ×
− 2.8 ± 1.2 106.2 ± 7.0 0.3 ± 0.1 111.6 ± 9.5 42,094 100 ×
− 3.7 ± 0.9 97.2 ± 4.8 0.1 ± 0.1 124.3 ± 8.8 210,470 500 ×
PFNA 500 µM − 3.5 ± 1.0 98.8 ± 4.4 0.5 ± 0.2 119.4 ± 7.6 10.925 1/10 ×
− 3.1 ± 1.0 107.6 ± 4.2 0.1 ± 0.1 126.4 ± 9.0** 109.25 1 ×
− 3.7 ± 0.9 109.9 ± 6.2 − 0.1 ± 0.1 113.2 ± 11.1 5462.5 50 ×
− 2.6 ± 1.4 108.4 ± 4.9 0.0 ± 0.1 119.5 ± 10.3 10,925 100 ×
− 2.1 ± 1.4 100.5 ± 6.6 0.7 ± 0.4 142.0 ± 6.9*** 54,625 500 ×
PFDA 100 µM − 2.7 ± 1.1 107.0 ± 4.1 − 0.6 ± 0.3 110.7 ± 8.3 3.754 1/10 ×
− 2.9 ± 1.0 116.2 ± 8.5 − 0.7 ± 0.4 100.6 ± 10.4 37.54 1 ×
− 3.1 ± 1.1 96.7 ± 6.0 − 0.6 ± 0.4 115.9 ± 12.5 1877 50 ×
− 2.9 ± 1.0 115.5 ± 3.3 − 0.4 ± 0.3 107.8 ± 8.7 3754 100 ×
− 3.0 ± 0.8 126.6 ± 11.5** − 0.6 ± 0.4 102.9 ± 5.6 18,770 500 ×
PFHxS 500 µM − 3.5 ± 1.0 112.3 ± 7.6 − 0.6 ± 0.4 108.0 ± 11.1 78.092 1/10 ×
− 3.0 ± 1.0 104.3 ± 5.7 − 0.8 ± 0.4 100.3 ± 9.4 780.92 1 ×
− 2.3 ± 1.6 99.5 ± 3.2 − 0.8 ± 0.4 113.4 ± 16.0 39,046 50 ×
− 3.2 ± 0.9 106.0 ± 5.6 − 0.7 ± 0.4 105.8 ± 13.3 78,092 100 ×
− 3.3 ± 1.0 112.5 ± 4.6 − 0.7 ± 0.4 106.9 ± 10.5 390,460 500 ×
PFUnDA − 3.7 ± 0.8 106.4 ± 4.9 − 0.9 ± 0.5 105.2 ± 11.6 3.368 1/10 ×
− 3.4 ± 1.0 106.5 ± 5.9 − 0.5 ± 0.3 105.6 ± 13.4 33.68 1 ×
− 2.2 ± 1.5 115.0 ± 5.1 − 0.9 ± 0.5 94.3 ± 8.0 1684 50 ×
− 3.2 ± 1.3 105.5 ± 5.7 − 0.7 ± 0.4 117.6 ± 11.8 3368 100 ×
− 3.4 ± 0.8 116.4 ± 9.2 − 0.6 ± 0.4 123.9 ± 13.8 16,840 500 ×
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When investigating potential EDCs, transactivation-
based assays such as reporter gene assays are commonly 
used to determine endocrine disrupting effects (Kjeldsen 
and Bonefeld-Jorgensen 2013; Frizzell et al. 2011). Only 
using transactivation-based assays to investigate AR-medi-
ated endocrine disruption limits the magnitude of endocrine 
disruption an EDC may induce. This is the case for PFOS 
1/10 × and 100 ×, PFOA 1/10 ×, and PFNA 1 × as each of 
these PFAAs increased AR translocation yet did not show 
any effect in terms of AR transactivation. Therefore, mak-
ing conclusions based solely upon one aspect of receptor 
signalling may lead to false-negative results as compounds 
may induce an endocrine disrupting effect via different 
molecular mechanisms. Further investigation to determine 
the effect of PFAA-induced AR translocation in the nucleus 
would potentially elucidate the full extent by which AR sig-
nalling is disrupted. Molecular biology techniques such as 
chromatin-immunoprecipitation combined with sequencing 
Fig. 6  Translocation effects of 6-h exposure to PFAAs on the andro-
gen receptor in recombinant AR U-2 OS cell line. a Analysing AR 
translocation activity following exposure to PFAAs + PC compared 
to the PC alone. Figure includes representative images of the antago-
nist test; upper panels = channel 1 (nucleus), middle panels = chan-
nel 2 (EGFP-AR localisation), and lower panels = composite (chan-
nel 1 + channel 2). Results are representative of three independent 
exposures (n = 3, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 
0.001. Only significant results are presented. × 10 objective magnifi-
cation. Scale bars = 100 µm
Fig. 7  Illustration of possible 
AR transactivation effects 
observed in the current study 
vs a recent study. Bell curve is 
based upon results reported in 
LNCaP cells following DHT 
exposure (Lee et al. 1995). 
Comparison between recent 
study (Kjeldsen and Bonefeld-
Jorgensen 2013) and the current 
study which may explain the 
biphasic effects on AR transac-
tivation associated with PFDA 
exposure. PC positive control 
(50 nM testosterone), DHT 
dihydrotestosterone
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followed by transcriptional analysis would determine the 
epigenetic changes induced by PFAAs and the effect on sub-
sequent transcription of AR target genes responsible for cell 
growth and proliferation, thus providing an in-depth analysis 
of the mechanism of action by which PFAAs disrupt AR 
signalling.
Recent work by Kjeldsen and Bonefeld-Jorgensen (2013) 
demonstrated that PFOS at 50 µM and PFDA at 100 µM 
antagonised AR transactivation. Despite concentrations 
of PFOS between the two studies being vastly different 
(Table 2), an antagonistic effect was seen in both studies 
suggesting that once the antagonistic effect is achieved (500 
×) it is maintained at higher concentrations (50 µM) and is 
not limited to the cell model used to express the AR-lucif-
erase reporter construct. The conflicting PFDA result may 
be explained by the fact that PFDA was used at 0.02 µM in 
the current study, a 5000-fold reduction in the concentration 
used in the Kjeldsen and Bonefeld-Jorgensen (2013) study.
A possible reason for the contrasting PFDA result 
may be explained by a biphasic effect. The PCa cell line 
LNCaP is androgen-dependent for growth and prolifera-
tion in vitro (Schuurmans et al. 1988; Sonnenschein et al. 
1989; Bélanger et al. 1990). DHT exposure from  10–12 M 
to  10–10 M positively increases cell growth by AR-mediated 
signalling until a shutoff point > 3 ×  10–10 M. At this point 
cell growth ceases and regresses. In another study, LNCaP 
cells exhibited a clear biphasic bell-shaped dose response 
curve for DHT exposure (Lee et al. 1995). Stipulating cell 
proliferation and growth is positively correlated with AR 
transactivation; this may explain the contrasting results in 
the current study and the study by Kjeldsen and Bonefeld-
Jorgensen (2013). An illustration of this is shown in Fig. 7. 
Despite difference in methodology and experimental design 
between each of the studies, the core biological dependency 
is the same as all cells are dependent AR signalling and the 
experimental outcome is AR transactivation. Current results 
therefore reiterate the importance of exposure concentra-
tion levels in vitro, and given our exposure concentration is 
based upon actual human blood data, our results are much 
more relevant to human exposure and health. Furthermore, 
disruption of AR signalling may cause AR-mediated health 
effects such as PCa (Mamsen et al. 2017; Eke et al. 2017). 
In Swedish men, blood-based levels of PFAAs were posi-
tively correlated with PCa risk and increased AR transacti-
vation. Therefore, it is possible PFAAs are involved in the 
pathogenesis of PCa by contributing to the overstimulation 
of androgenic signalling via the AR, and our study is the first 
to demonstrate this at human-based exposure levels in vitro.
Conclusion
PFAA concentrations based upon the exposure profile of the 
human Scandinavian population disrupt AR signalling by 
two different biological mechanisms. The first is mediated 
by increasing receptor translocation (PFOS 1/10 × and 100 
×, PFOA 1/10 ×, and PFNA 1 ×) leading to an increased 
presence of AR in the nucleus. The second is by disrupting 
AR transactivation (PFOS 500 × and PFDA 500 ×). PFAA 
exposure and PCa are health concerns in Scandinavian coun-
tries such as Norway and Sweden. Exposure to such PFAAs 
may contribute to AR-mediated adverse health effects such 
as PCa by disrupting AR signalling. Further investigation 
into the mechanism by which PFAAs increase AR transloca-
tion is needed, in addition to the epigenetic, transcriptional, 
and proteomic profiling of increased PFAA-induced nuclear 
AR, to fully address the endocrine disrupting effect and 
possible etiology for AR-related health effects such as PCa. 
Additionally, PFAAs at specified concentrations which dis-
rupted AR transactivation were not the same as those which 
disrupted AR translocation, thus addressing the necessity of 
using more than one method to evaluate endocrine disrupt-
ing potential of PFAAs and the wider category of POPs.
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